Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × Influenza Vaccines × Clear all

Phase

Status

Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 2 Lymphoma 2 Skin Neoplasms 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Osteosarcoma 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Metabolic Diseases 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunologic Deficiency Syndromes 1 Hepatoblastoma 1 Ganglioneuroblastoma 1 Anemia, Aplastic 1

Interventions

Cyclophosphamide 21 venetoclax 19 Dexamethasone 17 pembrolizumab 16 fludarabine 14 Cytarabine 13 Gemcitabine 10 Azacitidine 9 pomalidomide 8 Rituximab 8 Lenalidomide 8 Carboplatin 8 selinexor 7 glofitamab 7 fludarabine phosphate 7 Cisplatin 7 daratumumab 6 Temozolomide 6 Paclitaxel 6 Injections 6 Granulocyte Colony-Stimulating Factor 6 Oxaliplatin 5 Immunotherapy, Adoptive 5 Decitabine 5 ruxolitinib 4 Surgical Procedures, Operative 4 Nivolumab 4 Drug Therapy 4 Cladribine 4 Calcium Dobesilate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07502287 2026-03-30

DUAL-NK-NB

Beijing Biotech

Phase 1/2 Recruiting

Neuroblastoma, Recurrence, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡